An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 3

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Comparator: placebo; Drug: MK0478 (muraglitazar)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00130806

2005_020

0478-065

Details and patient eligibility

About

This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes (a specific type of diabetes) who are not currently treated with insulin.

Full description

The duration of treatment is 30 weeks.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• People between the ages of 18 and 70 who have a specific type of diabetes called type 2 diabetes which is currently being treated only with oral medication(s). (Patients currently taking insulin would not be allowed to participate.)

Exclusion criteria

• People who have specific diseases (such as liver disease, gallbladder disease, pancreatitis, severe blood disorders or history of neoplastic diseases) which will be discussed by the study doctor and for which study participation would not be allowed.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind